Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.54 |
| ▸ | CA1 | P00915 | 5/20 | 0.54 |
| ▸ | CA2 | P00918 | 5/20 | 0.54 |
| ▸ | CA9 | Q16790 | 5/20 | 0.54 |
| ▸ | ITK | Q08881 | 3/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8705236 | 0.96 | CA12 (0.53) | CA12CA1CA2CA9ITK | |
| SCHEMBL20100194 | 0.95 | CA12 (0.56) | CA12CA1CA2CA9ITK | |
| SCHEMBL29856376 | 0.95 | CA12 (0.56) | CA12CA1CA2CA9ITK | |
| SCHEMBL17687916 | 0.93 | CA12 (0.50) | CA12CA1CA2CA9ITK | |
| SCHEMBL17687929 | 0.90 | CA12 (0.49) | CA12CA1CA2CA9ITK | |
| SCHEMBL31192622 | 0.87 | CA12 (0.55) | CA12CA1CA2CA9ITK | |
| SCHEMBL23019541 | 0.87 | MAOA (0.42) | CA12CA1CA2CA9ITK | |
| SCHEMBL15153582 | 0.85 | CA1 (0.47) | CA12CA1CA2CA9ITK | |
| SCHEMBL17208794 | 0.85 | CA12 (0.65) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL15075255 | 0.84 | POLB (0.57) | CA12CA1CA2CA9ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220517-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-11 | — | — | US | disclosed |
| US-20190211036-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220517-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | BMI1, MLLT1, MEN1 | CA12 4567/4885CA1 4114/4885CA2 4457/4885 |
| US-20190211036-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | BMI1, MLLT1, MEN1 | CA12 4716/4885CA1 4420/4885CA2 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.